Day One Biopharmaceuticals to Acquire Mersana Therapeutics
Day One Biopharmaceuticals has announced a definitive merger agreement to acquire Mersana Therapeutics, enhancing its portfolio with the antibody-drug conjugate emiltatug ledadotin (Emi-Le), currently in Phase 1 trials for adenoid cystic carcinoma type-1. The deal includes a tender offer of $25 per share in cash, plus potential milestone payments, totaling up to $55.25 per share, with an overall deal value of approximately $285 million.
Day One Biopharmaceuticals has entered into a definitive merger agreement to acquire Mersana Therapeutics, expanding its portfolio with the novel antibody-drug conjugate emiltatug ledadotin (Emi-Le). Emi-Le is currently being studied in a Phase 1 trial for adenoid cystic carcinoma type-1 (ACC-1), a cancer with high unmet need. The agreement includes a tender offer for all outstanding Mersana shares at $25 per share in cash at closing, plus a non-tradable contingent value right (CVR) per share with potential milestone payments of up to $30.25 per CVR in cash. The total consideration could reach up to $55.25 per share, representing a total deal value of approximately $285 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574976-en) on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
